Market Overview

Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

Related KERX
Mid-Day Market Update: Weight Watchers Jumps On Oprah Stake; Great Lakes Dredge & Dock Shares Drop
Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares Slip On Weak Preliminary Q3 Results

In a report published Wednesday, Dawson James Securities reiterated its Market Outperform rating and $4.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX).

Dawson James Securities noted, “We maintain our Market Outperform rating and $4 price target on KERX shares. We derive our $4 price target by the synthesis of our DCF valuation ($3.73), comparables analysis (~$5.00), and our standardized CAGR methodology ($5.77). Risks to our valuation included clinical and regulatory, partnering, competitive, reimbursement, intellectual property and financial.”

Keryx Biopharmaceuticals closed on Tuesday at $2.93.

Latest Ratings for KERX

Oct 2015Morgan StanleyUpgradesUnderweightEqual-weight
Aug 2015Morgan StanleyInitiates Coverage onUnderweight
Aug 2015Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for KERX
View the Latest Analyst Ratings

Posted-In: Dawson James SecuritiesAnalyst Color Reiteration Analyst Ratings


Related Articles (KERX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters